Summit Therapeutics stock is trading -45.22% below its average target price of $37.66 after marking a 4.6% during today's afternoon session. Analysts are giving the Large-Cap Pharmaceutical company an average rating of buy and target prices ranging from $30.100424 to $44.192406 per share.
The stock has an unusually large proportion of its shares sold short at 22.1%, and a short ratio of 4.48. The company's insiders own 84.32% of its outstanding shares, which indicates a strong alignment between management and shareholder interests. Finally, we also note that a very small number of institutional investors are invested in the stock, with 13.5% of Summit Therapeutics's shares being owned by this investor type.
Institutions Invested in Summit Therapeutics
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2025-03-31 | Baker Bros. Advisors, LP | 3% | 24,424,865 | $503,640,736 |
| 2025-03-31 | Vanguard Group Inc | 2% | 11,640,507 | $240,027,264 |
| 2025-03-31 | FMR, LLC | 1% | 9,338,223 | $192,554,166 |
| 2025-03-31 | Blackrock Inc. | 1% | 8,397,556 | $173,157,611 |
| 2025-03-31 | Price (T.Rowe) Associates Inc | 1% | 6,557,804 | $135,221,923 |
| 2025-03-31 | State Street Corporation | 1% | 4,851,388 | $100,035,624 |
| 2025-03-31 | Geode Capital Management, LLC | 0% | 3,284,882 | $67,734,269 |
| 2025-03-31 | Pictet Asset Management Holding SA | 0% | 2,661,604 | $54,882,276 |
| 2025-03-31 | Balyasny Asset Management LLC | 0% | 1,703,180 | $35,119,573 |
| 2025-03-31 | Charles Schwab Investment Management, Inc. | 0% | 1,460,717 | $30,119,985 |
Besides an analyst consensus of strong upside potential, other market factors point to there being mixed market sentiment on Summit Therapeutics.
